Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 16.
doi: 10.1007/s11239-025-03212-0. Online ahead of print.

Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients aged ≥ 60 years with acute ischemic stroke by THRIVE scale

Nikolay A Shamalov  1 , Zhanna Yu Chefranova  2 , Elena B Yarovaya  3   4 , Vladimir A Kutsenko  3 , Natalya A Marskaya  1 , Andrey M Semenov  5 , Mikhail P Semenov  5 , Sergey V Ivanov  6 , Yulia A Romashova  6 , Sergey S Markin  7
Affiliations

Prognostic outcome of intravenous thrombolysis with non-immunogenic staphylokinase in patients aged ≥ 60 years with acute ischemic stroke by THRIVE scale

Nikolay A Shamalov et al. J Thromb Thrombolysis. .

Abstract

This study aimed to assess the prognostic value of the THRIVE scale in patients aged ≥ 60 years with acute ischemic stroke (AIS) after intravenous thrombolysis with the non-immunogenic staphylokinase compared with alteplase. The post-hoc analysis of FRIDA trial results was performed and enrolled patients aged ≥ 60 years were divided into two groups in accordance with the modified Rankin scale (mRS) score on day 90: good-outcome (mRS 0-2) and poor-outcome (mRS 3-6) groups. The receiver operating characteristic (ROC) curves were compared using Delong test. For all-cause mortality on day 90 the predicted AUC value by the THRIVE scale was 0.8 (0.71-0.9) in the non-immunogenic staphylokinase group and 0.76 (0.66-0.87) in the alteplase group (p = 0.57). For poor outcome, AUC value was 0.73 (0.64-0.82) in the non-immunogenic staphylokinase group and 0.79 (0.71-0.87) in alteplase group (p = 0.36). Thus, our study confirmed the prognostic value of the THRIVE scale to predict the outcomes of the patients aged ≥ 60 years treated with the non-immunogenic staphylokinase.

Keywords: Acute ischemic stroke; Non-immunogenic staphylokinase; Thrombolysis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

References

    1. Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, Fisher M, Pandian J, Lindsay P (2022) World stroke organization (WSO): global stroke fact sheet. Int J Stroke 17(1):18–29. https://doi.org/10.1177/17474930211065917 - DOI - PubMed
    1. Saposnik G, Cote R, Phillips S, Gubitz G, Bayer N, Minuk J, Black S, Stroke Outcome Research Canada (SORCan) Working Group (2008) Stroke outcome in those over 80: a multicenter cohort study across Canada. Stroke 39(8):2310–2317. https://doi.org/10.1161/STROKEAHA.107.511402 - DOI - PubMed
    1. Kastrup A, Brunner F, Hildebrandt H, Roth C, Winterhalter M, Gießing C, Papanagiotou P (2017) Thrive score predicts clinical and radiological outcome after endovascular therapy or thrombolysis in patients with anterior circulation stroke in everyday clinical practice. Eur J Neurol 24(8):1032–1039. https://doi.org/10.1111/ene.13328 - DOI - PubMed
    1. Flint AC, Cullen SP, Faigeles BS, Rao VA (2010) Predicting long-term outcome after endovascular stroke treatment: the totaled health risks in vascular events score. AJNR Am J Neuroradiol 31(7):1192–1196. https://doi.org/10.3174/ajnr.A2050 - DOI - PubMed - PMC
    1. Collen D (1998) Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nat Med 4:279–284. https://doi.org/10.1038/nm0398-279 - DOI - PubMed

LinkOut - more resources